Information  X 
Enter a valid email address

Indivior PLC (INDV)

  Print      Mail a friend

Thursday 16 May, 2019

Indivior PLC

Indivior to Participate in Conference

RNS Number : 1647Z
Indivior PLC
16 May 2019

Indivior to Participate in Jefferies 2019 Healthcare Conference


Slough, UK and Richmond, VA - May 16, 2019 - Indivior PLC (LON: INDV) today announced that Shaun Thaxter, Chief Executive Officer, and Mark Crossley, Chief Financial Officer, will participate in Jefferies 2019 Healthcare Conference taking place in New York City on June 4 to 7, 2019.


On Tuesday, June 4th at 10:30 a.m. EST, Thaxter will discuss Indivior's strategy and outlook. His remarks will be webcast live and the broadcast will be available on the "Investors" section of Indivior's website ( under "Webcasts / Audiocasts / Presentations." If you plan to listen to the live webcast, please allow sufficient time to register and download any audio software required to access the discussion.



About Indivior

Indivior is a global specialty pharmaceutical company working to change patient lives by pioneering life-transforming treatment for addiction and other serious mental health diseases. Our Vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit to learn more.



Jason Thompson


Vice President, Investor Relations

[email protected]



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t